Related Experiment Video
Updated: Jul 21, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Top Melanoma Articles from 2021 to Inform Your Cancer Practice
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484, P.O. Box 301402, Houston, TX, 77230-1402, USA. jgershen@mdanderson.org.
Abstract:
Advances in our understanding of melanoma biology and the role of immune checkpoint blockade and targeted therapy have ushered in a new and rapidly evolving era of multidisciplinary care for patients with melanoma. Based on efficacy for patients with metastatic melanoma, these systemic treatment approaches have been introduced into the adjuvant and, more recently, the neoadjuvant landscape. This report highlights the results of key clinical studies published or initially presented in 2021 that have informed our evidence-based approach to melanoma multidisciplinary care, primarily related to adjuvant and neoadjuvant approaches for patients with resectable or resected stage III or high-risk stage II melanoma and their impact on clinical care. Knowledge concerning these areas of active clinical investigation is critical for surgical oncologists who care for melanoma patients as the treatment landscape continues to evolve.
Insights
New systemic therapies, including immune checkpoint blockade and targeted therapy, are transforming adjuvant and neoadjuvant melanoma treatment for stage II and III patients. These advances are critical for surgical oncologists managing evolving melanoma care.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma treatment has evolved with advances in understanding tumor biology.
- Immune checkpoint blockade and targeted therapies show efficacy in metastatic melanoma.
Purpose of the Study:
- To review key 2021 clinical study results impacting melanoma multidisciplinary care.
- To focus on adjuvant and neoadjuvant approaches for resectable or resected stage III/high-risk stage II melanoma.
Main Methods:
- Review of clinical studies published or presented in 2021.
- Focus on systemic treatment approaches (adjuvant/neoadjuvant).
- Analysis of impact on clinical care for resectable or resected melanoma.
Main Results:
- Adjuvant and neoadjuvant systemic therapies are increasingly integrated into melanoma care.
- These approaches are based on efficacy data from metastatic melanoma trials.
- Clinical studies from 2021 inform evidence-based multidisciplinary care strategies.
Conclusions:
- Understanding adjuvant and neoadjuvant melanoma treatments is crucial for surgical oncologists.
- The evolving treatment landscape necessitates continuous knowledge updates.
- Multidisciplinary care is key for optimizing outcomes in high-risk melanoma patients.
